Sarepta Therapeutics, INC DEF 14A proxy statements
Proxy statements, covering the matters put to shareholders at the annual meeting — board elections, auditor ratification and executive pay.
NASDAQ
Sarepta Therapeutics is seeking shareholder approval for new 2026 equity and stock purchase plans while managing a leadership transition following the announced retirement of CEO Douglas Ingram.
NASDAQ
Sarepta Therapeutics has filed a definitive proxy statement with the SEC regarding its upcoming shareholder meeting.
NASDAQ
Sarepta Therapeutics is asking stockholders to approve amendments to its equity incentive and employee stock purchase plans to increase the number of shares available for issuance.
NASDAQ
Sarepta Therapeutics' proxy statement details proposals for the 2024 annual meeting, including director elections, executive compensation approval, and auditor ratification, while also providing insights into the company's governance, executive compensation, and sustainability efforts.
NASDAQ
Sarepta Therapeutics has filed a definitive proxy statement with the SEC, signaling upcoming shareholder actions.